All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec005}
============

National Medicines Regulatory Agencies (NMRAs) are responsible for carrying out a number of regulatory functions including: registration and marketing authorization, vigilance, market surveillance and control, licensing establishments, laboratory testing, clinical trials oversight and NMRA lot release, just to mention a few \[[@pone.0236332.ref001]\]. All these activities require adequate financial resources to assure the quality, safety and efficacy of medical products on the market and promotion of patient safety as a critical part of the health care delivery system \[[@pone.0236332.ref002]\]. Studies show that this important task of regulating medical products is often under-funded and under-recognized in many countries in Africa \[[@pone.0236332.ref002]\].

Sustainable funding is one of the key factors to ensure effective regulation of medical products, others include a comprehensive legal framework, appropriate and adequate governance mechanisms, and sound technical expertise \[[@pone.0236332.ref003]\]. The legal basis gives the NMRA power to perform a function. However, there are a number of prerequisites to its performance. These include, the level of autonomy in executing its mandate, the appropriate structure that allows for proper coordination of various regulatory activities, availability of financial resources and adequate number and type of appropriately skilled human resources with requisite competency to carry out their duties \[[@pone.0236332.ref004]\].

Sustainability of financial resources for NMRAs means having a specific budget assigned to medicines regulation and assurance that the allocated funds are safeguarded against the competing needs of other government agencies \[[@pone.0236332.ref004]\]. NMRAs funding sources can be derived from public funding, fees for services provided and donations to supplement the often limited funding available from government \[[@pone.0236332.ref005],[@pone.0236332.ref006]\]. The stability of an NMRA depends on its financing mechanism \[[@pone.0236332.ref006]\].

Globally, medicines regulators struggle with the need for financial and technical resources to fully meet their mandate. Generally, NMRAs from well-resourced countries such as the United States of America have reliable funding. For instance, the US Food and Drug Administration (US-FDA) budget for 2019 financial year is estimated at USD 5.7 billion, 55% of which (USD 3.1 billion) is provided by the federal government and the remaining 45% (USD 2.6 billion) is paid for by industry user fees \[[@pone.0236332.ref007]\]. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) employs mixed funding arrangements where the [Department of Health and Social Care](https://en.wikipedia.org/wiki/Department_of_Health_(United_Kingdom)) (DHSC) funds regulation of [medical devices](https://en.wikipedia.org/wiki/Medical_device), whilst the costs of [medicines](https://en.wikipedia.org/wiki/Medicines) regulation is met through fees from the [pharmaceutical industry](https://en.wikipedia.org/wiki/Pharmaceutical_industry) \[[@pone.0236332.ref008]\]. Studies conducted in Sub-Saharan Africa, on the other hand, have shown that in nine out of the twenty six States studied (34.6%) the NMRAs depend on government funding with all fees paid directly to treasury and not redistributed. In addition funds allocated by the States to their respective NMRAs are not released on time \[[@pone.0236332.ref005]\].

Due to limited publications on sustainable financing models for NMRAs, especially in low-middle income countries, this study is intended to contribute to the existing knowledge on the various funding sources for NMRAs, factors affecting sustainability and to propose sustainable funding options using the East Africa Community (EAC) as a case study.

Methodology {#sec006}
===========

An exploratory, mixed method design using both qualitative and quantitative data, was employed in this study. Data was collected from all the six NMRAs in the EAC partner States namely, the Republic of Burundi, Republic of Kenya, Republic of Rwanda, the United Republic of Tanzania (with two NMRAs), and the Republic of Uganda. Data from six NMRAs was collected through a combination of semi-structured interviews, questionnaires and checklists as indicated in [S1 File](#pone.0236332.s001){ref-type="supplementary-material"}, for the period 2011/12-2014/15 while 2010/11 data served as baseline.

Questionnaire and checklist were developed based on the information obtained from the preliminary situational analysis study. Moreover, additional questions were adopted from the WHO Global benchmarking tool for evaluation of national regulatory systems \[[@pone.0236332.ref001]\]. Validation of the questionnaire and checklists was done using a pilot study.

The first phase of data collection involved self-administration of the questionnaire and checklists ([S1 File](#pone.0236332.s001){ref-type="supplementary-material"}) by the selected informants. These included the NMRA's head, one monitoring and evaluation personnel from each NMRA and a project officer from the EAC MRH project, making a total of 13 respondents. All informants were purposefully selected based on their roles and participation in medicines policy and regulation of medical products in the respective NMRA.

Semi-structured interviews, also involving the above-mentioned respondents, were conducted following the successful completion of the questionnaire and checklists data collection phase. In addition, one NMRA staff responsible for medicines registration, GMP inspections, legal affairs, human resource and finance were also interviewed in each NMRA. An invitation letter and interview topic guide were sent to the interviewees in advance. Interviews were conducted on face to face basis, each session lasting for 1 to 2 hours. Responses were recorded by means of selective written notes, which were thereafter subjected to qualitative analysis. Follow up visits were conducted aiming at collecting the missing data and validating the previously collected data.

Due to lack of data from some agencies, only the available data set was used in statistical analysis and interpretation. The prevailing average annual USD currency exchange rate for each country was used for analysis. The average annual exchange rates of Tanzanian, Kenyan, Ugandan, Rwandese and Burundian currencies against the USD ranged as TZS (1585.3--2188.2), KES (84.2--101.5), UGX (2349.4--3369.4), RWF (579.9--783.1) and BIF (1159.7--1657.6) respectively over the studied period \[[@pone.0236332.ref009]\].

NMRAs financing was assessed using six (6) indicators namely: NMRA financing policy, level of NMRA autonomy, the total annual budget for carrying out regulatory functions, actual funding per annum, funds received from various sources, and the NMRA expenditure as shown under indicators guidance notes [S2 File](#pone.0236332.s002){ref-type="supplementary-material"}.

Quantitative data were analysed for means and standard deviation using Microsoft Excel^©^, whereas document analysis was used to extract organize and interpret data from policies and laws. This study was part of a larger overall evaluation of the NMRAs implementing medicines regulatory harmonization program in the EAC.

Ethical clearance {#sec007}
-----------------

Ethics approval was granted by the WITS Human Research Ethics Committee on 31^st^ July 2015 through clearance certificate No. M150751. In addition, national ethical clearance was granted by respective national research ethics committees and ministries of health. Informed consent forms were signed by individual respondents from NMRAs in the EAC partner states.

Results {#sec008}
=======

Funding policies and laws of NMRAs {#sec009}
----------------------------------

All six NMRAs provided data on their national medicines policies (NMPs) and medicines laws. While all the NMPs emphasise the need for effective regulation of medical products, policy commitment on funding NMRAs varies across countries. For semi- or fully autonomous NMRAs such as the Tanzania Medicines and Medical Devices Authority (TMDA), the National Drug Authority in Uganda (NDA), the Pharmacy and Poisons Board in Kenya (PPB), the Rwanda Food and Drugs Authority (Rwanda FDA) and the Zanzibar Food and Drug Agency (ZFDA), the laws provide for collection of fees from industry and its utilization to perform regulatory services \[[@pone.0236332.ref010]--[@pone.0236332.ref014]\]. However, in Burundi, the NMRAs was observed to be fully reliant on government funding during the studied period \[[@pone.0236332.ref015]\].

Level of NMRA financial autonomy {#sec010}
--------------------------------

There has been a progressive transformation of the level of financial autonomy of NMRAs in the EAC region over the study period ([Table 1](#pone.0236332.t001){ref-type="table"}). While Burundi NMRA is not autonomous, the Bill to transform the existing unit to an autonomous agency is at an advanced stage of consideration by her parliament \[[@pone.0236332.ref016]\]. In Rwanda on the other hand, the Food and drugs act of 2013 \[[@pone.0236332.ref011]\] has been enacted to establish the Rwanda Food and Drugs Authority (Rwanda FDA) as a semi-autonomous Agency. In Zanzibar, the former Zanzibar Food and Drugs Board (ZFDB) has been transformed into Zanzibar Food and Drugs Agency (ZFDA) by the Zanzibar Food, Drugs and Cosmetics Act number 2 of 2006 \[[@pone.0236332.ref013]\] with financial autonomy under the oversight of an Advisory Board. The existing laws in Kenya, Uganda and Tanzania-Mainland, provide for financial autonomy and empower the respective NMRAs to collect and utilise fees for services rendered \[[@pone.0236332.ref010],[@pone.0236332.ref012],[@pone.0236332.ref014]\].

10.1371/journal.pone.0236332.t001

###### Level of NMRA autonomy in the EAC partner states between the years 2011 and 2015.

![](pone.0236332.t001){#pone.0236332.t001g}

  Indicator                  National Medicines Regulatory Agency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  NMRA's level of autonomy   Department within the Ministry of Health                                                                                            Semi-Autonomous                                                                           Semi-Autonomous                                                                                                                         Semi-Autonomous                                                                                                                  Autonomous                                                              Semi-Autonomous
  Medicine Law               Republic of Burundi. Decret No. 100/150 du 30 September 1980 portant Organization de I'exercise de la Pharmacie au Burundi. 1980.   Republic of Kenya. The Pharmacy and Poisons Act, Chapter 244. 1957, as amended in 2009.   Republic of Rwanda. Law No. 47/2012 of 14/01/2013 relating to the Regulation and Inspection of Food and Pharmaceutical Products. 2013   United Republic of Tanzania (Mainland). Tanzania Food, Drugs and Cosmetics Act, Cap 219. 2003, as amended in 2004, 2014 & 2019   Republic of Uganda. The National Drug Policy and Authority Act. 1993.   United Republic of Tanzania (Zanzibar). The Zanzibar Food, Drugs and Cosmetics Act. No. 2 of 2006 as amended in 2016

NMRAs annual budgets {#sec011}
--------------------

The average total annual budget for all the countries for the period 2011--2015 ranged from USD 824,328.67 to USD 10,724,536.5 as shown in [Fig 1](#pone.0236332.g001){ref-type="fig"}, with Zanzibar and Uganda NMRAs having the lowest and highest average total annual budgets respectively. The NMRAs in Tanzania and Kenya exhibited almost similar average annual budgets, while the data for this indicator was not available for Burundi's and Rwanda's NMRAs. When compared to their own baselines, the total annual budget of each NMRA approximately doubled over a duration of five years.

![Trends in East African Community national medicines regulatory authorities' annual budgets.](pone.0236332.g001){#pone.0236332.g001}

NMRAs annual funding {#sec012}
--------------------

Comparison of the total annual budget against actual funding per annum shows an average of 54.8% (USD 458,970.11), 98.7% (USD 10,302,295.25) and 100% (USD 7,375,802.08) for Zanzibar Food & Drugs Agency (ZFDA), Uganda National Drug Authority (NDA) and Tanzania Medicines and Medical Devices Authority (TMDA) respectively, for years 2011--2015. However, data from Kenya and Rwanda under this aspect was not available ([Fig 2](#pone.0236332.g002){ref-type="fig"}). The 54% funding for ZFDA may entail either a problem with setting an unrealistic budget or simply that funding was inadequate to support NMRA activities.

![Trends in annual funding among national medicines regulatory authorities in the East African Community.](pone.0236332.g002){#pone.0236332.g002}

Sources of revenue for NMRAs {#sec013}
----------------------------

Assessment of the various sources of funds received by the NMRAs indicated governments, industry fees, and donors to be the major funding sources across all NMRAs as shown in [Fig 3](#pone.0236332.g003){ref-type="fig"}. It should be noted that the PPB in Kenya only provided data on annual budgets without indicating the sources of its revenue. For the NMRAs in Tanzania-mainland (TMDA) and Uganda (NDA), industry fees were observed to be the major source of funds. On average, industry fees contributed up to 73.20% and 98.25% of the total annual revenue for TMDA NDA respectively. For Zanzibar (ZFDA) and Burundi NMRAs, the governments were observed to be the main sources of revenue with Burundi relying solely on the government funding while for ZFDA, on average government contributes 50.40%, industry fees 40.60% and the remaining 9% of the total revenue is from donors and other sources.

![Annual mean amounts and sources of funds received by National medicines regulatory authorities.](pone.0236332.g003){#pone.0236332.g003}

Funds received from donors indicated a high degree of variation, with some NMRAs receiving funding only once over a five years duration, while others received fluctuating amounts with no remarkable trends. Funding partners most cited include the Bill and Melinda Gates Foundation (BMGF), World Health Organization (WHO), United Nations Industrial Development organization (UNIDO), Clinton Health Access Initiative (CHAI), United Nations International Children's Fund (UNICEF), Management Sciences for Health (MSH), World Bank, Trademark East Africa Limited (TMEA), German Corporation for International Cooperation (GIZ), Global Fund, the United States Pharmacopoeia (USP) and the United States Agency for International Development (USAID) just to mention a few. On average, the overall contribution of funds received from donors by each NMRA was the least among other sources of financing.

NMRAs' expenditure {#sec014}
------------------

Observation of expenditure patterns indicated operational costs to be the major expense in the majority of the NMRAs, followed by salaries and infrastructure development as shown in [Fig 4](#pone.0236332.g004){ref-type="fig"}. This is also explained by the observed increase in the number of staff among the NMRAs from which the annual number of staff could be obtained ([Fig 5](#pone.0236332.g005){ref-type="fig"}). The PPB in Kenya indicated the highest degree of average expenditure across all three categories, with the least average expenditures being marked by the Burundi NMRA. Data from Rwanda and Zanzibar NMRAs were not available for this indicator. The operational costs on average increased considerably across all the NMRAs during the studied period.

![Mean annual amounts and main areas of expenditure by the national medicines regulatory authorities.](pone.0236332.g004){#pone.0236332.g004}

![Annual trend in the number of staff per national medicines regulatory authority.](pone.0236332.g005){#pone.0236332.g005}

Discussion {#sec015}
==========

Clear government policy and legal framework to empower the NMRAs to collect and utilise fees for services offered is an essential element for sustainable funding \[[@pone.0236332.ref004]\]. Results from this study show that governments across the EAC region use different NMRA financing models to regulate pharmaceutical markets. While some rely entirely on government funding as is the case for Burundi NMRA, others use a combination of sources of revenue from government (50.40%), industry fees (40.60%) and donors and other sources (9%) as exemplified by ZFDA out of an average annual budget of USD 824,328.67. In the case of TMDA with the annual budget increasing from USD 3,384,123.00 to USD 9,422,888 and the contribution of industry fees to the total budget increasing over the years from 60% (USD 2,018,608.88) in 2011 to 86% (USD 8,123,093) in 2015, while the contribution from government has been steady at an average of 19.60% (USD 1,168,299.09) over the studied period. Yet, the government of Uganda largely depends on industry fees (98.25%, USD 8,077,238.20) to finance the NDA activities. The increase in revenue could be associated with the observed improvement in registration processes following the harmonization of registration systems and the introduction of quality management systems among the EAC Partner States \[[@pone.0236332.ref017]\].

Findings from this study are in agreement with the WHO multi-country study conducted in 2002 \[[@pone.0236332.ref004]\]. The WHO study reported a decrease from 100% to 60% donor funding between 1995 and 1997 in Uganda as the result changes in the NMRA funding policy, with the government and industry fees making up only 20% each. Currently, the Uganda NDA is 98.25% (USD 8,077,238.20) funded through fees for service with minimal contribution from donors. While there is no enough data for comparison with other EAC countries, the findings support the need for sound government policies and legal frameworks to empower the NMRA to collect and utilise fees as means to ensure financial sustainability \[[@pone.0236332.ref004]\].

In terms of an enabling environment for fees collection by the NMRAs, while the NMRAs in Kenya, Tanzania, Uganda, Rwanda, and Zanzibar have legal mandate to collect and utilise fees, Burundi does not. Considering that medical products regulation is a public function, safeguarding funding for regulation of medical products against the competing needs of other government agencies is key for sustainability of NMRAs.

An alternative funding model is a combination of government budgetary allocation and industry fees, whereas the collected fees are transferred to the government central treasury as is the case for Malaysia and Venezuela \[[@pone.0236332.ref004]\]. This is in line with the study among Sub-Saharan African countries, which revealed that 35% of the NMRAs depend on government funding, with all fees paid directly to Treasury \[[@pone.0236332.ref005]\]. It has also been reported that the fees and charges are set arbitrarily and not necessarily linked to the cost of service provided while resource intensive services are offered free \[[@pone.0236332.ref004]\]. Therefore, for this model to be sustainable, the existing fees and other charges should reflect the real cost of services provided. Under such conditions, the NMRA can rely entirely on the charged fees to finance regulatory activities. In a situation where the collected fees are transferred to the government central treasury, the government must ensure that the funding allocation meets the budget requirement. While it is important that NMRAs are adequately financed to deliver on their mandate, attention should also be given on NMRAs expenditure to ensure accountability and balanced utilization of funds for public interest \[[@pone.0236332.ref004]\].

Another model is where the fees and charges reflect the real cost of services provided such as evaluation of dossiers and inspection of establishments, and the NMRA is financed entirely on fees for service as is the case with the Therapeutic Goods Administration (TGA) in Australia and Medicines Control Authority of Zimbabwe (MCAZ) which have full powers to use the revenue they collect \[[@pone.0236332.ref004]\]. The TGA in Australia is an example of an agency that moved gradually from government-financed to a self-financed agency through a government policy which was phased in over a five years period from 1994--1999. Industry fees, therefore, provide a reliable and sustainable source of revenue for NMRAs.

This is especially so as Africa witnesses convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic diseases which is attributed to the USD 45 to 60 billion projection of the African pharmaceutical market by 2020 \[[@pone.0236332.ref006]\]. The increasing demand for medicines in Africa including the EAC region attributed by population and economic growth as well as raising consumer awareness warrants governments' investment on regulation of medical products \[[@pone.0236332.ref018]\].

Furthermore, governments investment in regional harmonization efforts and strengthening regulatory capacity and systems across NMRAs in the EAC partner states has a significant impact in improving availability of medicines through timely marketing authorization of essential medicines, reduced duplication of individual NMRAs efforts, streamlined use of limited resources with resultant savings in public health budgets \[[@pone.0236332.ref019],[@pone.0236332.ref020]\]. This is exemplified by the EAC medicines regulatory harmonization program which has increased efficiency in registration processes among the NMRAs in the region with a subsequent reduction in registration timelines from the previous 1--2 years period to a median of 7 months \[[@pone.0236332.ref021]\].

In recognition of the need to ensure that all African citizens have access to safe, quality and efficacious essential medicines, the African Union approved the African Medicines Regulatory Harmonization (AMRH) Initiative as a key pillar of the Pharmaceutical Manufacturing Plan for Africa (PMPA) \[[@pone.0236332.ref022]\]. The AMRH Initiative which covers more than 85% of Sub-Saharan Africa serves as a foundation for establishment of the African Medicines Agency. AMA will build on the AMRH success through coordination of on-going regulatory systems and strengthening and harmonization efforts of the AU, RECs, Regional Health Organization (RHOs) and member States \[[@pone.0236332.ref023]\]. AMA also provides a good platform to support the ongoing African Continental Free Trade Area (AfCFTA)---anchored pharmaceutical project for the Small Island States (SIDS) and land locked countries including Seychelles, Madagascar, Comoros, Mauritius, Djibouti, Eritrea, Rwanda, Ethiopia, Kenya, Sudan and IGAD. This pilot health and economic initiative established through public-private partnerships and innovative financing is intended to contribute to improved accessibility and affordability to safe medicines and to accelerated progress towards SDGs and Agenda 2063. All these initiatives provide an opportunity to invest in medicines regulation on the African continent.

Limitations of the study {#sec016}
========================

In this study, data on population size, the number of pharmaceutical establishments and the pharmaceutical market size was intended to determine the level of investment (in terms of financial and human resources) required to control the market. However, only Burundi provided data on pharmaceutical market size making analysis and comparison between countries difficult.

It is also worthwhile noting another limitation in this study as a lack of information on the actual NMRAs fees structure which provides different streams of fees charged and how the funds collected are distributed in performing the different regulatory functions. A further study on fees charged by different NMRAs will provide useful information on fees structure and its basis as well as proportion of contribution from various streams of revenues.

Conclusion {#sec017}
==========

Inadequate funding for NMRAs is one of the major challenges hampering effective regulation of medical products world-wide and within the East African Community. Measures are needed to guide countries to institute appropriate policies and legal frameworks which will ensure that NMRAs are empowered to collect and utilise fees for services they offer. Where the NMRA is not fully mandated and the market size does not provide enough financial resources for the NMRAs to perform their functions effectively, governments must ensure a dedicated budget is allocated to facilitate NMRA performance. Governments should also invest in NMRAs participation in regional harmonization efforts which have proven to facilitate effective and efficient utilization of already limited resources while at the same time reducing the time taken for applicants to put the product on the market.

There is a need to conduct further research to assess the fee structure employed by various NMRAs to determine whether it reflects the actual cost of service or not. The study can also explore the proportion of contribution from various streams of revenue and how they are allocated to support various regulatory functions and NMRAs participation in regional harmonization efforts. In addition, a study correlating population, pharmaceutical market size, with the level of investment needed to ensure effective market control needs to be conducted. This will assist in guiding governments on the level of investment needed for the NMRA in terms of infrastructure, financial and human resources, to ensure effective regulation of pharmaceutical market in a country.

Supporting information {#sec018}
======================

###### Questionnaire and checklist for heads of NMRAs and M&E experts.

(PDF)

###### 

Click here for additional data file.

###### Indicators guidance notes.

(PDF)

###### 

Click here for additional data file.

###### Data.

(PDF)

###### 

Click here for additional data file.
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9\. Line 217- Please spell out QMS and IMS.

10\. Please review the grammar in the discussion.

11\. Line 242- use of the word "dispose" seems awkward, consider alternative such as "use the revenue".

12\. In lieu of pharmaceutical market size data, one could possibly show, as some kind of possible indication of market size perhaps, the number of medicines listed on the national essential medicines lists. This data is available here: <https://global.essentialmeds.org/dashboard/countries>

If used, this publication can be cited for the source:

Persaud, N., Jiang, M., Shaikh, R., Bali, A., Oronsaye, E., Woods, H., & al., e. (2019). Similarities and Differences in Essential Medicines Lists of 137 Countries: a quantitative analysis. . Bull World Health Organ.

13\. In the discussion, the need for government investment is noted, but I think the opportunities to collect revenue from industry should also be stated as a key source again. Given the projections in market expansion, it seems only fair that industry should not only profit but also be contributing to NMRA activities from which they will ultimately benefit.

14\. State opportunities with the African Medicines Regulatory Authority?

15\. It seems that paragraph lines 277-284 should be in the discussion rather than conclusion (see comment above on industry funding in discussion). This is too much detail for the conclusion.

16\. References require proper formatting.

17\. Are there more references to cite on effectiveness of regulatory harmonization?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236332.r002

Author response to Decision Letter 0

4 Apr 2020

Reviewer 1 Comment

Inconsistent use of terms like TFDA and TMDA being used interchangeably throughout the document.

Author's response

TFDA has been replaced with TMDA throughout the document

Reviewer 1 Comment

Methodology:

The method being mixed method approach has a quantitative and qualitative component of data. However, the number of respondents for each country and their general demographic detail (age, gender, qualification, experience of working, level of engagement with NMRA etc.), an interview or meeting guide need to be shared to support study methodology.

Author's response

Added the following in methodology: "Data from six NMRAs was collected through a combination of semi-structured interviews, questionnaires and checklists for the period 2011/12-2014/15 while 2010/11 data served as baseline. Interviews were conducted with heads of NMRAs and monitoring and evaluation experts of the respective agencies" Page 2, lines 28-31; and Pages 5-6, lines 105-

Reviewer 1 Comment

The source of primary data collection (e.g, official notifications, reports, webpage of the NMRA etc) is missing (see Page 5, line 105-106).

Author's response

As stated above, the sources of primary data collection have been added on the methodology section:

Data from six NMRAs was collected through a combination of semi-structured interviews, questionnaires and checklists for the period 2011/12-2014/15 while 2010/11 data served as baseline.

Interviews were conducted with heads of NMRAs and monitoring and evaluation experts of the respective agencies Pages 5-6, lines 105-109

Reviewer 1 Comment

It seems that the review of NMP was a component of methodology as discussed latter in results (subheading 1) but needs to be mentioned here with the sources accessed for retrieving data on funds and policies.

Author's response

Added in methodology the following text:

"as shown under indicators guidance notes S2 Table",

to reflect the indicators used for analysis such as 'NMRA funding policy'

Changed the title of subheading in results to read

"Funding Policies and Laws of NMRAs"

Page 6, lines 119-120

Page 7, line 132

Reviewer 1 Comment

The exchange rate applied needs to be mentioned properly "prevailing average annual USD currency exchange rate" is insufficient to serve the purpose.

Author's response

The phrase has been omitted from the abstract.

The ranges of average annual exchange rates over the studied period are now included.

The authors think it will be more confusing to include the annual average for each country over six years, lowest and highest rates during this period are given instead. Page 6, lines 113 - 116

Reviewer 1 Comment

Results:

Subheading 1:

Page 6, line 127-128: Is the financial autonomy laid down in the NMP (please mention clearly)

Author's response

While national medicines policies provide an overarching government commitment to establish NMRAs, it is the medicines law which provide financial autonomy.

Medicines laws provide for legal power for NMRAs to collect and utilize fees. I have added medicines laws in the sub-heading and text to reflect this

Added a phrase "national medicines policies (NMPs) and medicines laws" for clarity

Page 7, line 133-135

Reviewer 1 Comment

Subheading 2

Page 7, line 129-131: Needs clear representation of data to support this. It will be nice to add a table with description of each country's information under financial autonomy status (Y/N), if Y since (year), under law or rule (State the rule/act or law reference), year of passing and enactment of law

Author's response

Included Table 1 on the level of NMRA autonomy in the EAC Partner States with respective laws and year of enactment and/or amendment Page 7 line 156-158

Reviewer 1 Comment

Subheading 3

Page 7, line 142-144: The figure represents the annual trend only so it can be described in a separately.

Author's response

Figure 1 and 2 are now described separately (under two subheadings) Page 7-8, lines 159 - 179

Reviewer 1 Comment

Subheading 4

Page 8, line 166: PPA (Please expand abbreviation on first use)

Page 8, line 167-170: Please rephrase to more concise \....

73.20% and 98.25%, respectively over the reported duration.

Page 9, line 178-182: It will be nicer to mention the funding agencies contributing up to a certain amount limit or above it for each country to make it more quantifiable to relate to the figure 4.

Author's response

The abbreviation PPB (Pharmacy and poisons Board) is used and explained for the first time in Page 7 line 135

Rephrased for clarity: "On average, industry fees contributed up to 73.20% and 98.25% of the total annual revenue for TMDA NDA respectively."

Individual contribution of each funding partner was not within the scope of the collected data. The data on all funds from these agencies were obtained collectively.

Page 7, line 137

Page 9, line 186-188

Reviewer 1 Comment

Subheading 5

Page 9, line 192: PPB??

Page, line 194-195. Addition of a figure on annual trend need will make the results clearer and more understandable.

Page 9, line 196-200: The point can be shifted to limitations of the study. Moreover, what could have been easily added is the population size and the year wise and/or country wise HR strength of the technical and nontechnical personnel in the NMRA as something that can explain the expenditure.

Author's response

The abbreviation PPB (Pharmacy and poisons Board) is used and explained for the first time in Page 7 line 132

Shifted the following text to limitations of the study:

"In this study, data on population size, the number of pharmaceutical establishments and the pharmaceutical market size was intended to determine the level of investment (in terms of financial and human resources) required to control the market. However, only Burundi provided data on pharmaceutical market size making analysis and comparison between countries difficult".

A figure capturing the trends of human resource for all NMRAs has been selected (Figure 5).

Page 7, line 137

Pages 14, lines 301-311

Reviewer 1 Comment

Discussion

Reference 6 is closely related to the objective and design of the study and is recommended to be discussed the results of the study.

Author's response

Reference 6 is not retrievable from a peer reviewed journal or any other internet accessible source (unpublished). It is therefore dropped, and other references are used in discussion of the study

Reviewer 1 Comment

Page 10, line 218: Reference 7 is unpublished, Authors should try to used published references for the details discussed here (references for improved regulatory systems in the countries under study for the study period)

Author's response

Changed reference and replaced with 'The Compendium of Quality Management System (QMS) Technical Documents for Harmonization of Medicines Regulation in the East African Community' which was published in 2014 (Ref number 17) Page 11, line 231-234

Reviewer 1 Comment

Conclusion:

Lapses in timely release of funds is not mentioned in the results nor data extraction from the interviews or meetings was disclosed in the article which could support this conclusion. Results need to be more explicit to support qualitative segment

Author's response

Deleted 'timely release of funds' Page 15, line 320

Reviewer 1 Comment

References:

Reference formatting needs attention for uniform style.

Author's response

All references have been formatted as per the PLOS ONE style Pages 16 -- 19, Lines 346-407

Reviewer 2 Comment

Insufficient detail on methods -- how was data analyzed?

E.g. NMPs- was there a document analysis?

Author's response

Added the following in methodology:

"Quantitative data were analyzed for means and standard deviation using Microsoft Excel©, whereas document analysis was used to extract organize and interpret data from policies and laws"

Page 6, lines 121-124.

Reviewer 2 Comment

Are the NMP stipulations legally binding? The discussion indicates this, but it is not clear.

Author's response

While national medicines policies provide an overarching government commitment to establish NMRAs, it is the medicines law which provide financial autonomy.

Medicines laws provide for legal power for NMRAs to collect and utilize fees.

We have now added medicines laws in the sub-heading and text to reflect this Page 7, line 132

Reviewer 2 Comment

Line 146- 148 says each budget approx. doubled, but it is difficult to discern this about the ZFDA in Fig. 1. Suggest editing figure to include smaller intervals on Y axis.

Author's response

Figures 1 -- 4 have been edited to expand the y-axis. However, due to big differences between highest and lowest values, it was difficult to do further expansion than in the current state. Figures 1 -- 4.

Reviewer 2 Comment

Throughout the paper, "N" is used to denote a USD amount. Please double check whether the use is correct, as I am not familiar with the use of N for a dollar amount (rather only for total population or sample).

Author's response

Deleted 'N' associated with \$ sign and replaced the dollar sign with USD throughout the text Throughout the text

Reviewer 2 Comment

It should be noted why there is no data for Kenya and Rwanda for Fig. 2.

Author's response

The phrase "However, data from Kenya and Rwanda under this aspect was not available" has been included. Page 9, line 175

Reviewer 2 Comment

Can the scale for Fig. 3 also be changed to capture the low amounts better?

Author's response

The scale of figure 3 on the y-axis has been changed to better capture the low amounts. Figure 3

Reviewer 2 Comment

While donor contributions to NMRAs may vary, it would be interesting to know which of the donors provided the most funding, per country and perhaps overall.

Author's response

Difficult to quantify in a meaningful way. Individual contribution of each funding partner was not within the scope of the collected data. The data on all funds from these agencies were obtained collectively

Reviewer 2 Comment

Fig. 4- It looks as though the SDs are negative. I am not a statistician, but I do not think that's possible. Suggest a basic statistical review and/or make this clearer in the figure.

Author's response

This was possible due to the high variability in annual expenditures of some aspects. Some standard deviation values were therefore larger than the means, which is a possible occurrence. However, to avoid confusions, we have conducted a statistical review and omitted the outliers. See revised figures 3 and 4.

Reviewer 2 Comment

Line 217- Please spell out QMS and IMS.

Author's response

Included... 'quality management systems for QMS' and dropped IMS

Text now reads: "The assumption is that the increase in revenue could be associated with the improvement in registration processes especially following harmonization of registration systems and the introduction of quality management systems among the EAC Partner States" Page 11, line 233

Reviewer 2 Comment

Author's response

Reviewer 2 Comment

Please review the grammar in the discussion.

Author's response

The grammar in the discussion has been reviewed. Page 11-14

Reviewer 2 Comment

Line 242- use of the word "dispose" seems awkward, consider alternative such as "use the revenue".

Author's response

Agreed, the phrase has been changed to "to use the revenue they collect" Page 12, lines 265-266

Reviewer 2 Comment

In lieu of pharmaceutical market size data, one could possibly show, as some kind of possible indication of market size perhaps, the number of medicines listed on the national essential medicines lists. This data is available here:

<https://global.essentialmeds.org/dashboard/countries>

If used, this publication can be cited for the source:

Persaud, N., Jiang, M., Shaikh, R., Bali, A., Oronsaye, E., Woods, H., & al., e. (2019). Similarities and Differences in Essential Medicines Lists of 137 Countries: a quantitative analysis. . Bull World Health Organ.

Author's response

The reference and link provide global status of essential medicines list per country which may not necessarily give an indication of the pharmaceutical market size

Reviewer 2 Comment

In the discussion, the need for government investment is noted, but I think the opportunities to collect revenue from industry should also be stated as a key source again. Given the projections in market expansion, it seems only fair that industry should not only profit but also be contributing to NMRA activities from which they will ultimately benefit

Author's response

Agreed, substantiated in the discussion Page 12, lines 268-269

Reviewer 2 Comment

State opportunities with the African Medicines Regulatory Authority?

Author's response

Added text on the African Medicines Regulatory Harmonization (AMRH) Initiative as a foundation for African Medicines Agency (AMA) in the discussion, also included Africa Continental Free Trade Area (AfCFTA) as another opportunity Pages 13-14, lines 285-299

Reviewer 2 Comment

It seems that paragraph lines 277-284 should be in the discussion rather than conclusion (see comment above on industry funding in discussion). This is too much detail for the conclusion.

Author's response

Agreed, the paragraph in lines 277 -- 284 has been removed from the conclusion and moved to the discussion section together with some rephrasing Page 12, lines 254-261

Reviewer 2 Comment

References require proper formatting.

Author's response

All references have been formatted as per the PLOS ONE style Pages 16 -- 18, Lines 346-407

Reviewer 2 Comment

Are there more references to cite on effectiveness of regulatory harmonization?

Author's response

Included References 22 and 23 Page 18, line 401 - 407

10.1371/journal.pone.0236332.r003
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: Overall the quality has improved, although it still requires more detail to properly understand steps taken to conduct this study and therefore to evaluate the validity of the findings. I think the discussion is very interesting now!

1\. While the title indicates that a case study methodology was used, the methods section does not. In my view the study did not take a case study approach (which is a methodology to intensively study a case for the purpose of understanding a larger population). I suggest to remove case study from the title as it may be misleading and replace it with something like "National Medicines Regulatory Authorities Financial Sustainability in The East African Community".

2\. Abstract Methodology: incorrect use of semi-colon, replace with commas. This is also the case on lines 62-64, 116-119 and a few more throughout the manuscript.

3\. Line 99: Reconsider case study use here, consider alternative wording (as per my comment 1).

4\. Whether semi-structured interviews were done and how is unclear, as there is no detailed information on participants or data collection in this regard. S1 indicates that respondents completed the questionnaire form on their own or perhaps it was administered by the study team? It appears that a descriptive analysis was done from a questionnaire, but it's hard to tell. If interviews were done, this requires a lot more detail, such as:

\- Was a topic guide used for the semi-structured interviews or was it based directly on the questionnaire (and thus perhaps not really semi-structured)?

\- How were participants selected, how many participants responded, what was the length and format of the interviews?

\- Were these audio-recorded and transcribed? How was data analyzed (more information so I could reproduce this)?

\- How was sampling conducted?

5\. In any case, it would help to have more participant information. Were participants all the heads of NMRAs participants and M&E experts (i.e. did all agree in each of the countries?), how many respondents were there total? Why were these specifically selected?

6\. Lines 108-109: In the follow-up visits, who provided the missing data at the agencies and who validated the data? How exactly was the data validated (e.g. official records)? Or how do you know it is reliable? Were these different respondents than the initial interviews?

7\. Related, where was the budget data obtained from specifically (official records, or did you rely on responses from individuals) and how was it validated if it was through responses?

8\. How was the questionnaire/ data collection tool developed? Detail is needed to understand what it is based on (any previously used standardized tools?) and its validity.

9\. Line 230-232: Why is this the assumption? Can you be more explicit?

10\. Line 234 (and throughout the manuscript): Check capitalizations, as these are inconsistent in some parts of the paper. I also think there is a typo here with "multi-county" instead of "multi-country".

11\. Line 240: pluralize sound government policies and legal frameworks?

12\. Line 247: typo with t before government?

13\. Line 271: "chronic lifestyle diseases" implies the conditions are a result solely of individual behaviours which is shown to be generally not true, suggest changing to non-communicable diseases or simply chronic conditions

14\. Line 314: "in particular" isn't necessary here

15\. PREVIOUS COMMENT

Reviewer 2 Comment

Throughout the paper, "N" is used to denote a USD amount. Please double check whether the use is correct, as I am not familiar with the use of N for a dollar amount (rather only for total population or sample).

Author's response

Deleted 'N' associated with \$ sign and replaced the dollar sign with USD throughout the text Throughout the text

REVIEWER REPLY: One 'N' was not deleted/missed on page 9.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

23 May 2020

Reviewer 2 Comment

Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Author's response

Agreed, the data underlying the findings described in the manuscript have been availed as Supporting information. (S2)

Reviewer 2 Comment

While the title indicates that a case study methodology was used, the methods section does not. In my view the study did not take a case study approach (which is a methodology to intensively study a case for the purpose of understanding a larger population). I suggest to remove case study from the title as it may be misleading and replace it with something like "National Medicines Regulatory Authorities Financial Sustainability in The East African Community". Authorities Financial Sustainability in The East African Community". (Line 1-2)

Author's response

We agree with the proposal. The title has been changed to read "National Medicines Regulatory

Reviewer 2 Comment

Abstract Methodology: incorrect use of semi-colon, replace with commas. This is also the case on lines 62-64, 116-119 and a few more throughout the manuscript.

Author's response

Agreed, incorrectly used semi-colons have been replaced with comas (Lines 38-44, 61-64, 137-139 and throughout the manuscript)

Reviewer 2 Comment

Line 99: Reconsider case study use here, consider alternative wording (as per my comment 1).

Author's response

The title has been changed to read "National Medicines Regulatory Authorities Financial Sustainability in the East African Community" (Line 1-2)

Reviewer 2 Comment

Whether semi-structured interviews were done and how is unclear, as there is no detailed information on participants or data collection in this regard. S1 indicates that respondents completed the questionnaire form on their own or perhaps it was administered by the study team? It appears that a descriptive analysis was done from a questionnaire, but it's hard to tell. If interviews were done, this requires a lot more detail, such as:

\- Was a topic guide used for the semi-structured interviews or was it based directly on the questionnaire (and thus perhaps not really semi-structured)?

\- How were participants selected, how many participants responded, what was the length and format of the interviews?

\- Were these audio-recorded and transcribed? How was data analyzed (more information so I could reproduce this)?

\- How was sampling conducted?

Author's response

Agreed, the following paragraphs have been added on the methodology section to provide more details about tools, mode and participants involved data collection:

"The first phase of data collection involved self-administration of the questionnaire and checklists (S1) by the selected informants. These included the NMRA's head, one monitoring and evaluation personnel from each NMRA and a project officer from the EAC MRH project, making a total of 13 respondents. All informants were purposefully selected based on their roles and participation in medicines policy and regulation of medical products in the respective NMRA." (lines 112 -117)

"Semi-structured interviews, also involving the above-mentioned respondents, were conducted following the successful completion of the questionnaire and checklists data collection phase. In addition, one NMRA staff responsible for medicines registration, GMP inspections, legal affairs, human resource and finance were also interviewed in each NMRA. An invitation letter and interview topic guide were sent to the interviewees in advance. Interviews were conducted on face to face basis, each session lasting for 1 to 2 hours. Responses were recorded by means of selective written notes, which were thereafter subjected to qualitative analysis. Follow up visits were conducted aiming at collecting the missing data and validating the previously collected data" (Lines 118 -- 126)

Reviewer 2 Comment

In any case, it would help to have more participant information. Were participants all the heads of NMRAs participants and M&E experts (i.e. did all agree in each of the countries?), how many respondents were there total? Why were these specifically selected?

Author's response

Yes, all heads of NMRAs and M&E experts from each country agreed to participate in the study. We have included the total number (13) of participants in questionnaire and checklist in the above response. Moreover, during semi-structured interviews 5 additional participants were interviewed. These were the staff responsible for medicines registration, GMP inspections, legal affairs, human resource and finance (also stated in the above response).

We selected all respondents based on their prevailing roles within the NMRA. This meant they were well informed on all aspects of relevance to the objectives of this study, hence enabling availability of more detailed and reliable information

Reviewer 2 Comment

Related, where was the budget data obtained from specifically (official records, or did you rely on responses from individuals) and how was it validated if it was through responses?

Author's response

Budget data was obtained from official records, heads of NMRAs signed consent form to make data available and agreed on publication of the outcome of research.

Reviewer 2 Comment

How was the questionnaire/ data collection tool developed? Detail is needed to understand what it is based on (any previously used standardized tools?) and its validity.

Author's response

"Questionnaire and checklists were developed based on the information obtained from the preliminary situational analysis study. Moreover, additional questions were adopted from the WHO Global benchmarking tool for evaluation of national regulatory systems. Validation of the questionnaire and checklists was done in pilot study involving 2 NMRAs." (Lines 108 -- 111)

Reviewer 2 Comment

Line 230-232: Why is this the assumption? Can you be more explicit?

Author's response

This assumption is based on findings from another unpublished study we conducted aiming at assessing the medicines registration and quality management systems in the East African Community, where we observed that the NMRAs which showed increased efficiency in marketing authorization process after the harmonization of registration systems.

For better clarity, we have rephrased the statement to read:

"The increase in revenue could be associated with the observed improvement in registration processes following the harmonization of registration systems and the introduction of quality management systems among the EAC partner States". (Lines 247 -249)

Reviewer 2 Comment

Line 234 (and throughout the manuscript): Check capitalizations, as these are inconsistent in some parts of the paper. I also think there is a typo here with "multi-county" instead of "multi-country".

Author's response

Agreed, capitalizations checked and corrected throughout the manuscript. The typo in "multi-county" has been corrected to "multi-country". (line 250 and throughout the manuscript)

Reviewer 2 Comment

Line 240: pluralize sound government policies and legal frameworks?

Author's response
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